Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: CVS stock price vs AAPL: inconclusive — current versus $42.08 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at AAPL's multiple
Implied fair value · at CVS's multiple
Needs CVS P/E.
Close Dec 31, 2025
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
17 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 98% equity / 2% debt · EV / Revenue 8.34x · EV proxy / EBITDA proxy 23.29x
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
CVS HEALTH Corp · implied price per share
Bear
$43.35
Base
$58.49
Bull
$78.21
Apple Inc. · implied price per share
Bear
$130.85
Base
$159.76
Bull
$182.30
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Walgreens Boots Alliance, Inc.
CVS vs WBA
UNITEDHEALTH GROUP INC
CVS vs UNH
Walmart Inc.
CVS vs WMT
Cigna Group
CVS vs CI
HUMANA INC
CVS vs HUM
Elevance Health, Inc.
CVS vs ELV
MICROSOFT CORP
CVS vs MSFT
Alphabet Inc.
CVS vs GOOGL
Meta Platforms, Inc.
CVS vs META
NVIDIA CORP
CVS vs NVDA
INTEL CORP
CVS vs INTC
CISCO SYSTEMS, INC.
CVS vs CSCO
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Edwyn research
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe CVS can materially expand margins and reduce leverage faster than the current data suggests, then avoid extrapolating the low sales multiple into upside; otherwise, the data favors caution or underweighting CVS because the stock appears expensive relative to its weak profitability and balance-sheet risk.
CVS trades at a much lower P/S and EV/Revenue than AAPL, but the apparent discount is offset by materially inferior earnings quality and balance-sheet risk. On the provided P/E-based valuation, CVS shows 51.6% downside to the implied price of $50.65 versus the current price of $104.75.
Supporting Metrics
